{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T20:45:03Z","timestamp":1785703503178,"version":"3.56.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82302936"],"award-info":[{"award-number":["82302936"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372708"],"award-info":[{"award-number":["82372708"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bbrc.2026.154109","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T03:49:36Z","timestamp":1780717776000},"page":"154109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Establishment and multi-omics characterization of a PD-1-resistant murine esophageal squamous cell carcinoma cell line"],"prefix":"10.1016","volume":"828","author":[{"given":"Yi","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luxi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunzhi","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6465-3540","authenticated-orcid":false,"given":"Sai","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2026.154109_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bbrc.2026.154109_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-074962","article-title":"Advances in diagnosis and management of cancer of the esophagus","volume":"385","author":"Deboever","year":"2024","journal-title":"Br. Med. J."},{"key":"10.1016\/j.bbrc.2026.154109_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-17450-2","article-title":"The circRNA circADAMTS6 promotes progression of ESCC and correlates with prognosis","volume":"12","author":"Bu","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2026.154109_bib4","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1080\/14796694.2025.2495542","article-title":"Tislelizumab for the treatment of advanced esophageal squamous cell carcinoma","volume":"21","author":"Shiraishi","year":"2025","journal-title":"Future Oncol."},{"key":"10.1016\/j.bbrc.2026.154109_bib5","article-title":"Comparison of PD-1 inhibitors in patients with advanced esophageal squamous cell carcinoma in the second-line setting","volume":"11","author":"Zhou","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbrc.2026.154109_bib6","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.ccell.2023.09.011","article-title":"Progenitor-like exhausted SPRY1+CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma","volume":"41","author":"Liu","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbrc.2026.154109_bib7","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.ccell.2023.03.016","article-title":"An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma","volume":"41","author":"Chen","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbrc.2026.154109_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.954992","article-title":"Managing the TME to improve the efficacy of cancer therapy","volume":"13","author":"Bilotta","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2026.154109_bib9","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/1078155220963538","article-title":"Immunotherapy in gastroesophageal cancers: current state and future directions","volume":"27","author":"Shaikh","year":"2021","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.bbrc.2026.154109_bib10","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1186\/s12885-023-11715-3","article-title":"PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): a network meta-analysis","volume":"23","author":"Zhao","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbrc.2026.154109_bib11","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12929-018-0468-7","article-title":"Tumor xenograft animal models for esophageal squamous cell carcinoma","volume":"25","author":"Lee","year":"2018","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.bbrc.2026.154109_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104068","article-title":"Preclinical tumor mouse models for studying esophageal cancer","volume":"189","author":"Mahmoudian","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bbrc.2026.154109_bib13","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.1038\/s41467-020-17492-y","article-title":"Single-cell transcriptomic analysis in a mouse model deciphers cell transition states in the multistep development of esophageal cancer","volume":"11","author":"Yao","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2026.154109_bib14","doi-asserted-by":"crossref","DOI":"10.4251\/wjgo.v17.i8.109489","article-title":"Unmasking immune checkpoint resistance in esophageal squamous cell carcinoma: insights into the tumor microenvironment and biomarker landscape","volume":"17","author":"Wang","year":"2025","journal-title":"World J. Gastrointest. Oncol."},{"key":"10.1016\/j.bbrc.2026.154109_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217600","article-title":"Characterization of novel mouse esophageal squamous cell carcinoma cell lines and their utility as preclinical models","volume":"616","author":"Li","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbrc.2026.154109_bib16","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1038\/s41388-023-02670-1","article-title":"A novel integrated approach to predicting cancer immunotherapy efficacy","volume":"42","author":"Luo","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2026.154109_bib17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40164-022-00277-y","article-title":"Heterogeneity of the tumor immune microenvironment and its clinical relevance","volume":"11","author":"Jia","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.bbrc.2026.154109_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14153692","article-title":"Advanced cellular models for preclinical drug testing: from 2D cultures to Organ-on-a-Chip technology","volume":"14","author":"Foglizzo","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbrc.2026.154109_bib19","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/gutjnl-2025-335642","article-title":"Alleviated T cell exhaustion and SLC1A3-mediated stroma-remodelling dictate chemoimmunotherapy efficacy in oesophageal squamous cell carcinoma","volume":"75","author":"Xiang","year":"2026","journal-title":"Gut"},{"key":"10.1016\/j.bbrc.2026.154109_bib20","article-title":"Discovery and validation of proliferative exhausted T cells as a favorable prognostic biomarker in esophageal squamous cell carcinoma","volume":"15","author":"Li","year":"2025","journal-title":"Sci. Rep."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26008739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26008739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T19:45:13Z","timestamp":1785699913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X26008739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":20,"alternative-id":["S0006291X26008739"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.154109","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Establishment and multi-omics characterization of a PD-1-resistant murine esophageal squamous cell carcinoma cell line","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.154109","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"154109"}}